The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Dysport
Botulinum Toxin Type A · BOTULINUM TOXIN TYPE A 300 U/1 · Injection, Powder, Lyophilized, For Solution · Intramuscular · Galderma Laboratories, L.P.
NDC 00299-5962-01 · 1 VIAL in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL · BLA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Ipsen Biopharm LtdUnited Kingdommanufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 3 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $1,564.61 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA125274
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Botulinum Toxin Type A (Injection, Powder, Lyophilized, For Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Galderma Laboratories, L.P. | BOTULINUM TOXIN TYPE A 300 U/1 | Jul 15, 2026 | Sep 2, 2026 |
| Ipsen Biopharmaceuticals, Inc. | BOTULINUM TOXIN TYPE A 300 U/1 | Jul 15, 2026 | Sep 2, 2026 |
| Ipsen Biopharmaceuticals, Inc. | BOTULINUM TOXIN TYPE A 500 U/1 | Jul 15, 2026 | Sep 2, 2026 |
| Revance Therapeutics, Inc. | BOTULINUM TOXIN TYPE A 100 U/1.2mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Dysport — NDC 00299-5962-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00299596201.
Free to cite with attribution — see how the data is put together.